Evidence map›Paper›PMID 41801496›Full record

ArticleWorld journal of microbiology & biotechnology2026

Improvement of enfumafungin production by Hormonema carpetanum via mutagenesis and process optimization: mutant generation and preliminary transcriptomic analysis.

Haodong Chen, Junyi Wang, Haolong Huang, Jiali Gui, Songbai Yang, Wen Tang, Jiawei Tang, Shaoxin Chen

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haodong ChenNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Junyi WangNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Haolong HuangNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Jiali GuiNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Songbai YangNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Wen TangNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Jiawei TangNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China.
Shaoxin ChenNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry, Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China. sxzlb@263.net.

Funding

National Key Research and Development Program of China 2021YFC2102100Shanghai Sailing Program 23YF1445700
6 · The paper itself

Abstract

Enfumafungin, a triterpenoid antifungal compound, serves as the key starting material for the synthesis of ibrexafungerp and SCY-247. However, its low fermentation yield and high production cost constrain its supply, limiting drug accessibility and the ability to meet clinical demand. Consequently, enhancing enfumafungin biosynthesis is crucial for achieving large-scale production. In this study, physical and chemical mutagenesis treatments were adopted for Hormonema carpetanum ATCC 74360, and a genetically stable high-producing mutant, H. carpetanum ENF-5-29, was generated. This mutant produced 817 mg/L enfumafungin in flasks, a 30-fold increase over that of wild-type ATCC 74360. Comparative transcriptome analysis revealed that the proposed biosynthetic pathway from glucose to enfumafungin presented the most significant upregulation in the mutant. The fermentation medium and conditions were subsequently optimized to further enhance enfumafungin production. Transcriptome analysis revealed improved yields under low-temperature culture, likely due to the upregulated expression of key genes in the mevalonate pathway and the enfumafungin biosynthetic gene cluster (BGC). Together, these transcriptome findings provide molecular insight into enhanced enfumafungin production. Furthermore, batch fermentation of ENF-5-29 in a 5 L bioreactor achieved a yield of 1,621 mg/L, the highest yield reported to date. Our results demonstrate the efficacy of mutagenesis for H. carpetanum improvement and pinpoint key targets for future genetic engineering aimed at enhancing enfumafungin biosynthesis.

Indexed as

MutagenesisAntifungal AgentsBiosynthetic PathwaysCulture MediaEchinocandinsFermentationGene Expression ProfilingGene Expression Regulation, FungalGlucoseMultigene FamilyMutationTranscriptomeTriterpenesAntifungal AgentsCulture MediaEchinocandinsGlucoseTriterpenesEnfumafunginFermentation cultureHormonema carpetanumMutagenesisTranscriptome analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.